Oculis Holding AG (NASDAQ:OCS) Given Average Rating of “Buy” by Brokerages

Shares of Oculis Holding AG (NASDAQ:OCS) have received an average rating of “Buy” from the six research firms that are covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $30.17.

Several research analysts have weighed in on the company. Robert W. Baird upped their target price on Oculis from $35.00 to $37.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 11th. HC Wainwright upped their price target on Oculis from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, June 11th. Bank of America decreased their price target on Oculis from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, June 11th. Finally, Chardan Capital reiterated a “buy” rating and set a $30.00 price target on shares of Oculis in a research note on Tuesday, June 11th.

Institutional Trading of Oculis

Hedge funds have recently added to or reduced their stakes in the business. abrdn plc bought a new stake in Oculis during the 4th quarter valued at approximately $15,980,000. Searle & CO. bought a new stake in Oculis during the 4th quarter valued at approximately $112,000. Finally, Compagnie Lombard Odier SCmA boosted its stake in Oculis by 47.3% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock valued at $1,053,000 after purchasing an additional 30,750 shares during the period. Institutional investors own 22.30% of the company’s stock.

Oculis Stock Performance

Shares of OCS stock opened at $11.69 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.71 and a quick ratio of 4.71. Oculis has a fifty-two week low of $9.05 and a fifty-two week high of $14.50. The stock’s 50-day moving average is $11.76 and its two-hundred day moving average is $11.93. The firm has a market cap of $473.45 million, a P/E ratio of -6.57 and a beta of 0.28.

Oculis (NASDAQ:OCS) last issued its earnings results on Wednesday, May 8th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.03). Oculis had a negative return on equity of 52.72% and a negative net margin of 6,712.02%. The firm had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.28 million. Analysts predict that Oculis will post -1.92 earnings per share for the current fiscal year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.